IM Cannabis Announces Form F-3 Resale Registration Statement Filing
Rhea-AI Summary
IM Cannabis (Nasdaq: IMCC) filed a Form F-3 resale registration statement with the SEC on June 9, 2026. The filing covers 17,276,931 common shares tied to three 2026 convertible promissory notes and accompanying warrants. If declared effective, selling shareholders may resell these shares; IM Cannabis will not receive proceeds.
Positive
- Form F-3 resale registration filed with SEC for 17,276,931 shares
Negative
- Registration covers 17,276,931 common shares for potential resale
- Company will not receive proceeds from selling shareholders’ share sales
News Market Reaction – IMCC
On the day this news was published, IMCC declined 8.70%, reflecting a notable negative market reaction. Argus tracked a trough of -21.9% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $176K from the company's valuation, bringing the market cap to $1.84M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Convertible note financing | Neutral | +1.8% | Closed US$225,000 convertible note and issued related warrants for funding. |
| May 13 | Q1 2026 earnings | Negative | -3.3% | Reported lower revenue, weaker margins and a net loss for Q1 2026. |
| May 07 | Convertible financings | Negative | -6.7% | Raised US$550,000 via discounted convertible notes with attached warrants. |
| Apr 10 | Nasdaq bid notice | Negative | +4.0% | Received Nasdaq notice for non‑compliance with $1.00 minimum bid rule. |
| Mar 31 | 2025 results | Positive | -9.3% | Reported C$54.7M 2025 revenue and positive operating cash flow turnaround. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News on financings and compliance often coincided with negative moves, while some fundamentally positive updates saw share price declines, indicating skepticism toward long-term turnaround efforts.
Over recent months, IMCC has combined turnaround messaging with continued financing and listing pressures. On Mar 31, audited 2025 results highlighted higher revenue and positive operating cash flow, yet shares fell 9.31%. A Nasdaq minimum bid notice on Apr 10 preceded a 3.99% gain. Multiple 2026 convertible note financings on Apr 6, May 7, and Jun 3 funded operations but added equity overhang, with mixed short-term reactions. Today’s Form F‑3 resale registration continues this pattern of financing-linked dilution risk.
Key Terms
form f-3 regulatory
resale registration statement regulatory
convertible promissory note financial
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Resale Registration Statement registered an aggregate of 17,276,931 common shares in the capital of the Company ("Common Shares") comprised of: (i) up to 4,000,000 Common Shares issued or issuable upon the conversion of a convertible promissory note dated April 6, 2026, in the principal amount of
The Resale Registration Statement has been filed with the SEC but has not yet become effective. A copy of the Resale Registration Statement will be available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. If declared effective by the SEC, the selling shareholders may use the prospectus relating to the Resale Registration Statement from time to time to resell the securities registered under the Resale Registration Statement. The Company will not receive any proceeds from the sale of any of the Common Shares by the selling shareholders.
This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities, including the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.
The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the review of the Resale Registration Statement by the SEC; the timing of, and whether, the Resale Registration Statement may be declared effective by the SEC; and the ability of the selling shareholders to resell the securities covered by the Resale Registration Statement pursuant to the prospectus, if and when the Resale Registration Statement is declared effective.
These forward-looking statements are based on a number of assumptions, including, among others: that the SEC review process will proceed in the ordinary course; that no material delays, objections or changes will arise in connection with the Resale Registration Statement; that the Company will continue to satisfy applicable regulatory and listing requirements; and that other factors relevant to the Resale Registration Statement and the resale of the underlying securities will not change in a material adverse manner.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: risks that the resale registration statement may not be declared effective on the timeline anticipated by the Company or at all; the possibility of changes in applicable laws, rules or regulatory requirements; the Company's ability to continue to comply with applicable listing requirements; adverse market conditions; and the other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar.
Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Michal Efraty
Investor & Public Relations
IM Cannabis Corp.
michal@efraty.com
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
info@imcannabis.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/im-cannabis-announces-form-f-3-resale-registration-statement-filing-302795829.html
SOURCE IM Cannabis Corp.